News
The best steroids for women are typically mild compounds like Anavar (Oxandrolone) and Winstrol (Stanozolol). These oral ...
GENFIT’s 2024 Universal Registration Document includes, in particular : The Statutory Auditors’ reports on the annual and consolidated financial statements and related-party agreements, The table ...
SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative ...
First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE ...
The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target ...
About CooperCompanies CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, ...
This exclusive private label distribution agreement with Smith+Nephew is a significant development for Nuo ,” commented David Jorden, Nuo’s Chief Executive and Financial Officer. “ We could not ...
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses; NXP900 has an acceptable ...
Conference Call and Webcast scheduled for tomorrow, April 30, 2025 at 10:00 am PT. SAN JUAN CAPISTRANO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ...
DUBLIN and BRIDGEWATER, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced it has regained compliance with the Nasdaq Stock Market (“Nasdaq”) continued ...
Continuing its commitment to advancing cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) is showcasing its patented Full Spectrum Profiling™ (FSP ®) technology at CYTO 2025 and American ...
Commercial Progress: The first full quarter of Attruby net product revenue was $36.7 million. As of April 25, 2025, 2,072 unique patient prescriptions for Attruby have been written by 756 unique ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results